PTPN11 and paraganglioma: Based on data from the SangerBox website, it was found that the expression of PTPN11 exhibited notable discrepancies (P < .05) between the remaining 25 types of cancer and control samples, except for kidney renal papillary cell carcinoma, kidney renal clear cell carcinoma, rectum adenocarcinoma, kidney chromophobe, pan-kidney cohort, lung squamous cell carcinoma, skin cutaneous melanoma, pheochromocytoma and paraganglioma, and adrenocortical carcinoma (Fig. 1A).